For colon cancer, conventional targeted therapies include epithelial growth factor receptor (EGFR) inhibitors (cetuximab and panitumumab)6,7, which slow down cancer growth, or vascular endothelial growth factor (VEGF) inhibitors (bevacizumab, ramucirumab, and Ziv-aflibercept)6,8, which suppress the angiogenesis process. The gene discussed is VEGFA; the disease is cancer.